Natco Pharma Gets Establishment Inspection Report From U.S. FDA For Telangana Facility 
Natco Pharma is investing to further establish its presence in Australia, Singapore, China and South East Asian countries, says Chairman VC Nannapaneni. (Photographer: Brent Lewin/Bloomberg)

Natco Pharma Gets Establishment Inspection Report From U.S. FDA For Telangana Facility 

Bookmark

Natco Pharma Ltd. on Saturday said it has received an establishment inspection report from the U.S. drug regulator for its Kothur facility in Telangana.

"The United States Food and Drug Administration had conducted pre-approval inspection at the company's drug formulations facility in Kothur village during the period from March 2 to 6, 2020," Natco Pharma said in a filing to the BSE.

The EIR signifies successful closure of inspection by the regulator, it added.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.